Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;24(1):83-91.
doi: 10.3802/jgo.2013.24.1.83. Epub 2013 Jan 8.

Advanced ovarian cancer: what should be the standard of care?

Barbara A Goff  1
Affiliations

Advanced ovarian cancer: what should be the standard of care?

Barbara A Goff. J Gynecol Oncol. 2013 Jan.

Abstract

The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to understand that epithelial ovarian cancer is a heterogeneous disease, our treatment strategies are evolving to include novel biologic drugs that specifically exploit altered pathways. Surgery remains an essential component in the treatment of ovarian cancer; however, the importance of surgical specialization and defining "optimal cytoreduction" as no visible residual disease has been further validated. Ongoing studies are defining the role of neoadjuvant chemotherapy in the upfront treatment of advanced ovarian cancer. In addition, clinical trials are evaluating intraperitoneal, dose dense, antiangiogenic drugs as well as targeted maintenance therapies which will establish new standards of care in the near future.

Keywords: Antiangiogenesis; Chemotherapy; Clinical trials; Dose dense chemotherapy; Intraperitoneal chemotherapy; Ovarian cancer; Surgery.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

    1. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–443. - PMC - PubMed
    1. Sfakianos GP, Secord AA, Shih lM. Epithelial ovarian cancers: low malignant potential and non-serous ovarian histologies. In: Karlan BY, Bristow RE, Li AJ, editors. Gynecologic oncology clinical practice & surgical atlas. New York: McGraw Hill Medical; 2012. pp. 237–256.
    1. Crum CP, McKeon FD, Xian W. The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol. 2012;55:24–35. - PMC - PubMed
    1. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma: evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226:421–426. - PMC - PubMed
    1. Vang R, Shih IeM, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62:44–58. - PubMed